Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - levetiracetam -

Malta - English - Malta Medicines Authority

remedica limited limassol industrial estate, aharnon street, 3056 limassol, cyprus - film-coated tablet - sitagliptin 25 mg - drugs used in diabetes

Malta - English - Malta Medicines Authority

remedica limited limassol industrial estate, aharnon street, 3056 limassol, cyprus - film-coated tablet - sitagliptin 50 mg - drugs used in diabetes

Malta - English - Malta Medicines Authority

remedica limited limassol industrial estate, aharnon street, 3056 limassol, cyprus - film-coated tablet - sitagliptin 100 mg - drugs used in diabetes

European Union - English - EMA (European Medicines Agency)

zoetis belgium sa - meloxicam - oxicams - dogs - alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders in dogs.

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

revital healthcare (epz) ltd., kenya - disposable sampler with viral transport medium , swabs -

United States - English - NLM (National Library of Medicine)

trell pharma, llc - lactobacillus acidophilus (unii: 1prr1v42v5) (lactobacillus acidophilus - unii:1prr1v42v5) - revitaflor is an orally administered prescription probiotic formulation for the clinical dietary management of suboptimal nutritional status in patients where advanced supplementation is required and nutritional supplementation in physiologically stressful conditions for maintenance of good health is needed. revitaflor should be administered under the supervision of a licensed medical practitioner.

Israel - English - Ministry of Health

amgen europe b.v. - adalimumab - solution for injection - adalimumab 50 mg / 1 ml - adalimumab - rheumatoid arthritisamgevita in combination with methotrexate is indicated for:• the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.• the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.amgevita can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.adalimumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function, when given in combination with methotrexate.axial spondyloarthritisankylosing spondylitis (as):amgevita is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.axial spondyloarthritis without radiographic evidence of as:amgevita is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as, but with objective signs of inflammation by radiological and/or laboratory tests including mri and serum crp levels, who have had an inadequate response to, or are intolerant to, non - steroidal anti-inflammatory drugs.psoriatic arthritisamgevita is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by x-ray in patients with polyarticular symmetrical subtypes of the disease to improve physical function.psoriasisamgevita is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.hidradenitis suppurativa (hs)amgevita is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adult patients with an inadequate response to conventional systemic hs therapy.crohn’s diseaseamgevita is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active crohn’s disease who have had an inadequate response to conventional therapy. amgevita is indicated for reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab.ulcerative colitisamgevita is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6- mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies.uveitisamgevita is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroidsparing, or in whom corticosteroid treatment is inappropriate.intestinal behcet's diseaseamgevita is indicated for the treatment of intestinal behcet’s disease in patients who have had an inadequate response to conventional therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - levetiracetam, quantity: 750 mg - tablet, film coated - excipient ingredients: purified talc; maize starch; colloidal anhydrous silica; magnesium stearate; povidone; titanium dioxide; sunset yellow fcf aluminium lake; polyvinyl alcohol; quinoline yellow aluminium lake; macrogol 3350; indigo carmine aluminium lake - use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation.

United States - English - NLM (National Library of Medicine)

blaine labs inc. - active ingredients, benzalkonium chloride (0.1%) - purpose antimicrobial uses     * 1st and 2nd degree burns     * stasis ulcers     * pressure ulcers     * diabetic ulcers     * lacerations     * abrasions     * skin tears     * surgical incision sites     * device insertion sites     * graft sites     * donor sites ask a doctor before use revitaderm wound care gel is for external use only. avoid contact with eyes. if you get it in your eyes, rinse immediately with cool tap water. revitaderm wound care gel may become discolored when it mixes with fluid from the wound. this is normal and not a cause for concern. do not use more than the recommended dose or use for longer than prescribed without checking with your doctor. talk with your doctor before you use any other medicines or cleansers on your skin. revitaderm wound care gel does not contain sunscreen. ask you doctor before you use revitaderm wound care gel if you must be outside for a long period of time. if your symptoms do not get better or if they get worse, check with your doctor.